Comments
Mangalam Drugs and Organics Limited announced it is expanding its anti-malaria active pharmaceutical ingredients (API) portfolio with pyronaridine, which was recently pre-qualified by the World Health Organization.
The shares of Mangalam Drugs and Organics Limited were trading at ₹121.68, up by ₹7.71 or 6.76 per cent, on the NSE at 2:05 pm.
The Bill and Melinda Gates Foundation is providing technical assistance for the backward integration of pyronaridine production to enhance cost-competitiveness. Medicine for Malaria Venture (MMV), a non-profit based in Geneva, has endorsed the pyronaridine-artesunate combination therapy for malaria treatment.
This development is expected to position Mangalam Drugs at the forefront of the global anti-malaria API production and drive significant growth and profitability for the company.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.